ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.34T | 45.61% |
2MRK | MERCK & CO INC | Healthcare | $362.27B | 12.30% |
3GILD | GILEAD SCIENCES INC | Healthcare | $208.31B | 7.08% |
4VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $137.57B | 4.67% |
5BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $127.39B | 4.33% |
6HCA | HCA HEALTHCARE INC | Healthcare | $104.58B | 3.55% |
7REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $98.40B | 3.34% |
8IDXX | IDEXX LABORATORIES INC | Healthcare | $54.99B | 1.87% |
9ONC | BEONE MEDICINES LTD | Healthcare | $47.50B | 1.61% |
10NTRA | NATERA INC | Healthcare | $46.83B | 1.59% |
11MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $34.43B | 1.17% |
12ILMN | ILLUMINA INC | Healthcare | $31.68B | 1.08% |
13DXCM | DEXCOM INC | Healthcare | $30.35B | 1.03% |
14INSM | INSMED INC | Healthcare | $25.90B | 0.88% |
15UTHR | UNITED THERAPEUTICS CORP | Healthcare | $25.27B | 0.86% |
16INCY | INCYTE CORP | Healthcare | $24.81B | 0.84% |
17THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 0.78% |
18ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $20.98B | 0.71% |
19NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.15B | 0.58% |
20EXEL | EXELIXIS INC | Healthcare | $17.04B | 0.58% |
21SMMT | SUMMIT THERAPEUTICS INC | Healthcare | $12.06B | 0.41% |
22HALO | HALOZYME THERAPEUTICS INC | Healthcare | $11.48B | 0.39% |
23HNGE | HINGE HEALTH INC | Healthcare | $9.83B | 0.33% |
24CORT | CORCEPT THERAPEUTICS INC | Healthcare | $8.07B | 0.27% |
25TXG | 10X GENOMICS INC | Healthcare | $7.77B | 0.26% |
26KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $7.56B | 0.26% |
27IMVT | IMMUNOVANT INC | Healthcare | $7.25B | 0.25% |
28KOD | KODIAK SCIENCES INC | Healthcare | $6.80B | 0.23% |
29ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $6.66B | 0.23% |
30IBRX | IMMUNITYBIO INC | Healthcare | $6.46B | 0.22% |
31MIRM | MIRUM PHARMACEUTICALS INC | Healthcare | $6.09B | 0.21% |
32DOCS | DOXIMITY INC | Healthcare | $5.92B | 0.20% |
33PTCT | PTC THERAPEUTICS INC | Healthcare | $5.29B | 0.18% |
34LQDA | LIQUIDIA CORP | Healthcare | $5.24B | 0.18% |
35TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $4.95B | 0.17% |
36IONS | IONIS PHARMACEUTICALS INC | Healthcare | $4.55B | 0.15% |
37VKTX | VIKING THERAPEUTICS INC | Healthcare | $3.52B | 0.12% |
38ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $3.14B | 0.11% |
39XNCR | XENCOR INC | Healthcare | $2.86B | 0.10% |
40RCUS | ARCUS BIOSCIENCES INC | Healthcare | $2.56B | 0.09% |
41BHVN | BIOHAVEN LTD | Healthcare | $2.13B | 0.07% |
42VIR | VIR BIOTECHNOLOGY INC | Healthcare | $2.08B | 0.07% |
43HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.98B | 0.07% |
44BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $1.98B | 0.07% |
45SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.72B | 0.06% |
46NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.06% |
47RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $1.66B | 0.06% |
48IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.57B | 0.05% |
49NVAX | NOVAVAX INC | Healthcare | $1.45B | 0.05% |
50ANAB | ANAPTYSBIO INC | Healthcare | $1.43B | 0.05% |
51NVCR | NOVOCURE LTD | Healthcare | $1.37B | 0.05% |
52INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.29B | 0.04% |
53FRNM | FREENOME INC | Healthcare | $1.14B | 0.04% |
54VSTM | VERASTEM INC | Healthcare | $1.06B | 0.04% |
55SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $859M | 0.03% |
56MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $844M | 0.03% |
57ALMS | ALUMIS INC | Healthcare | $793M | 0.03% |
58PHR | PHREESIA INC | Healthcare | $783M | 0.03% |
59DCTH | DELCATH SYSTEMS INC | Healthcare | $744M | 0.03% |
60FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $669M | 0.02% |
61CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $662M | 0.02% |
62OLMA | OLEMA PHARMACEUTICALS INC | Healthcare | $659M | 0.02% |
63CBIO | CRESCENT BIOPHARMA INC | Healthcare | $534M | 0.02% |
64RGNX | REGENXBIO INC | Healthcare | $531M | 0.02% |
65DMAC | DIAMEDICA THERAPEUTICS INC | Healthcare | $503M | 0.02% |
66OBIO | ORCHESTRA BIOMED HOLDINGS INC | Healthcare | $484M | 0.02% |
67ARVN | ARVINAS INC | Healthcare | $450M | 0.02% |
68PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.01% |
69NPCE | NEUROPACE INC | Healthcare | $413M | 0.01% |
70LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $385M | 0.01% |
71MPLT | MAPLIGHT THERAPEUTICS INC | Healthcare | $328M | 0.01% |
72ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $326M | 0.01% |
73CV | CAPSOVISION INC | Healthcare | $314M | 0.01% |
74AGEN | AGENUS INC | Healthcare | $311M | 0.01% |
75SPOK | SPOK HOLDINGS INC | Healthcare | $243M | 0.01% |
76DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.01% |
77GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $224M | 0.01% |
78TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.01% |
79STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.01% |
80CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.00% |
81IMUX | IMMUNIC INC | Healthcare | $106M | 0.00% |
82VTVT | VTV THERAPEUTICS INC | Healthcare | $83M | 0.00% |
83GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.00% |
84XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $2.94T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 84% toward Growth. +8% unclassified (16 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 84 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
At least 50% of total assets must sit in cash, government securities, other RICs, and other securities limited to 5% of assets and 10% of the issuer's voting securities per issuer.
Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.
Arithmetically entailed by '40 Act 5(b)(1) diversification (75%/5% asset leg) — it cannot fail independently, so it is reported outside the tally rather than counted as a separate check.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T052248 rates=20261113T052248
Measured on the 2026-11 formation date across 84 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 32.5% | 4.4% |
| 3 yearsp.a. | 24.7% | -3.4% |
| 5 yearsp.a. | 17.4% | 11.5% |
| 10 yearsp.a. | 14.8% | 8.9% |
| Since inceptionp.a. | 9.8% | 5.8% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 34.7% | 6.1% |
| 2025 | 23.3% | -23.2% |
| 2024 | 10.9% | 23.8% |
| 2023 | 8.6% | 3.9% |
| 2022 | 7.1% | 58.2% |
| 2021 | 9.1% | 34.0% |
| 2020 | 17.7% | -7.3% |
| 2019 | 20.2% | -10.4% |
| 2018 | 5.0% | 14.3% |
| 2017 | 15.1% | 10.3% |
| 2016 | -15.8% | 1.8% |
| 2015 | 9.6% | 6.8% |
| 2014 | 31.5% | 11.8% |
| 2013 | 50.9% | 0.5% |
| 2012 | 22.0% | 4.3% |
| 2011 | 21.4% | 25.9% |
| 2010 | 4.7% | -14.7% |
| 2009 | 14.8% | -14.1% |
| 2008 | -7.2% | 39.0% |
| 2007 | -0.8% | -20.1% |
| 2006 | 3.8% | 0.1% |
| 2005 | 8.3% | 19.5% |
| 2004 | 4.5% | -9.6% |
| 2003 | 7.3% | -20.7% |
| 2002 | -21.4% | 7.7% |
| 2001 | -15.1% | 18.2% |
| 2000 | 39.4% | 19.2% |
| 1999 | -3.7% | 22.5% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare CBOperProf Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a CBOperProf signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.